Targeting abnormal DNA double strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias

Resistance to imatinib (IM) and other BCR-ABL1 tyrosine kinase inhibitors (TKI)s is an increasing problem in leukemias caused by expression of BCR-ABL1. Since chronic myeloid leukemia (CML) cell lines expressing BCR-ABL1 utilize an alternative non-homologous end-joining pathway (ALT NHEJ) to repair...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Tobin, Lisa A., Robert, Carine, Rapoport, Aaron P., Gojo, Ivana, Baer, Maria R., Tomkinson, Alan E., Rassool, Feyruz V.
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3752989/
https://ncbi.nlm.nih.gov/pubmed/22641215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2012.203
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires